Korean J Urol.  2010 Jan;51(1):15-20.

mRNA Expression of S100A8 as a Prognostic Marker for Progression of Non-Muscle-Invasive Bladder Cancer

• Ha YS
• Kim MJ
• Yoon HY
• Kang HW
• Kim YJ
• Yun SJ
• Lee SC
• Kim WJ

Abstract

PURPOSE
S100A8 is a member of the S100 protein family containing 2EF-hand calcium-binding motifs. S100 proteins are involved in the regulation of a number of cellular processes such as cell cycle progression and differentiation. Altered expression of this protein is associated with various diseases and cancers. The present study aimed to evaluate whether S100A8 has prognostic value for non-muscle-invasive bladder cancer (NMIBC). MATERIALS AND METHODS: A total of 103 primary NMIBC samples obtained by transurethral resection were evaluated. mRNA levels were examined by real-time reverse transcriptase polymerase chain reaction (RT-PCR) analysis. The results were compared with clinico-pathological parameters. The Kaplan-Meier method was applied to plot the curves for progression-free survival. The multivariate Cox regression model was used to identify the independent prognostic factors for progression. RESULTS: mRNA expression levels of S100A8 were significantly related to the progression of NMIBC. Kaplan-Meier estimates demonstrated significant differences in tumor progression according to the level of S100A8 expression (log-rank test, p<0.001). The multivariate Cox regression model revealed that the S100A8 mRNA expression level (hazard ratio: 12.538; 95% confidence interval: 2.245-70.023, p=0.004) was an independent predictor for disease progression of NMIBC. CONCLUSIONS: Expression levels of S100A8 might be a useful prognostic marker for disease progression of NMIBC.

Keyword

Urinary bladder neoplasms; S100A8 protein; Polymerase chain reaction; Biological tumor markers

MeSH Terms

Calgranulin A
Cell Cycle
Disease Progression
Disease-Free Survival
Polymerase Chain Reaction
Reverse Transcriptase Polymerase Chain Reaction
RNA, Messenger
S100 Proteins
Biomarkers, Tumor
Urinary Bladder
Urinary Bladder Neoplasms
Calgranulin A
RNA, Messenger
S100 Proteins

Figure

• 

  FIG. 1 Receiver operating characteristic (ROC) curve generated for progression with the S100A8 mRNA expression level in non-muscle-invasive bladder cancer. AUC: area under the curve.

• 

  FIG. 2 Time to progression in non-muscle-invasive bladder cancer with S100A8 mRNA expression levels.

Reference

1. The statistics report: the incidence of cancer on 2003-2005 and the survival rate on 1993-2005. 2009. accessed Apr 1, 2009. National Cancer Center;http://www.ncc.re.kr.

2. Messing EM. Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, editors. Urothelial tumors of the bladder. Campbell-Walsh urology. 2007. 9th ed. Philadelphia: Saunders;2426–2427.

3. Wu TT, Chen JH, Lee YH, Huang JK. The role of bcl-2, p53, and ki-67 index in predicting tumor recurrence for low grade superficial transitional cell bladder carcinoma. J Urol. 2000. 163:758–760.

4. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou-Redorta J. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2008. 54:303–314.

5. Quan C, Park MS, Jo SW, Lee SC, Kim WJ. Effects of transforming growth factor-beta1 and its receptor on the development, recurrence and progression of human bladder cancer. Korean J Urol. 2006. 47:426–435.

6. Ha YS, Yun SJ, Kim YJ, Lee SC, Kim WJ. Utility of Smo as a prognostic marker for human bladder tumors. Korean J Urol. 2007. 48:997–1003.

7. Schäfer BW, Heizmann CW. The S100 family of EF-hand calcium-binding proteins: functions and pathology. Trends Biochem Sci. 1996. 21:134–140.

8. Marenholz I, Heizmann CW, Fritz G. S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature). Biochem Biophys Res Commun. 2004. 322:1111–1122.

9. Schäfer BW, Wicki R, Engelkamp D, Mattei MG, Heizmann CW. Isolation of a YAC clone covering a cluster of nine S100 genes on human chromosome 1q21: rationale for a new nomenclature of the S100 calcium-binding protein family. Genomics. 1995. 25:638–643.

10. Schutte BC, Carpten JD, Forus A, Gregory SG, Horii A, White PS. Report and abstracts of the sixth international workshop on human chromosome 1 mapping 2000. Iowa City, Iowa, USA. 30 September-3 October 2000. Cytogenet Cell Genet. 2001. 92:23–41.

11. Yong HY, Moon A. Roles of calcium-binding proteins, S100A8 and S100A9, in invasive phenotype of human gastric cancer cells. Arch Pharm Res. 2007. 30:75–81.

12. Yao R, Lopez-Beltran A, Maclennan GT, Montironi R, Eble JN, Cheng L. Expression of S100 protein family members in the pathogenesis of bladder tumors. Anticancer Res. 2007. 27:3051–3058.

13. Tolson JP, Flad T, Gnau V, Dihazi H, Hennenlotter J, Beck A, et al. Differential detection of S100A8 in transitional cell carcinoma of the bladder by pair wise tissue proteomic and immunohistochemical analysis. Proteomics. 2006. 6:697–708.

14. Salama I, Malone PS, Mihaimeed F, Jones JL. A review of the S100 proteins in cancer. Eur J Surg Oncol. 2008. 34:357–364.

15. Borden LS Jr, Clark PE, Hall MC. Bladder cancer. Curr Opin Oncol. 2003. 15:227–233.

16. Greene FL. The American Joint Committee on Cancer: updating the strategies in cancer staging. Bull Am Coll Surg. 2002. 87:13–15.

17. Hall MC, Chang SS, Dalbagni G, Pruthi RS, Seigne JD, Skinner EC, et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol. 2007. 178:2314–2330.

18. Bland JM, Altman DG. Transformations, means, and confidence intervals. BMJ. 1996. 312:1079.

19. Hsieh HL, Schäfer BW, Sasaki N, Heizmann CW. Expression analysis of S100 proteins and RAGE in human tumors using tissue microarrays. Biochem Biophys Res Commun. 2003. 307:375–381.

20. Cross SS, Hamdy FC, Deloulme JC, Rehman I. Expression of S100 proteins in normal human tissues and common cancers using tissue microarrays: S100A6, S100A8, S100A9 and S100A11 are all overexpressed in common cancers. Histopathology. 2005. 46:256–269.

21. Rafii S, Lyden D. S100 chemokines mediate bookmarking of premetastatic niches. Nat Cell Biol. 2006. 8:1321–1323.

22. Dyrskjot L, Kruhoffer M, Thykjaer T, Marcussen N, Jensen JL, Moller K, et al. Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res. 2004. 64:4040–4048.

23. Arai K, Takano S, Teratani T, Ito Y, Yamada T, Nozawa R. S100A8 and S100A9 overexpression is associated with poor pathological parameters in invasive ductal carcinoma of the breast. Curr Cancer Drug Targets. 2008. 8:243–252.

24. Hermani A, Hess J, De Servi B, Medunjanin S, Grobholz R, Trojan L, et al. Calcium-binding proteins S100A8 and S100A9 as novel diagnostic markers in human prostate cancer. Clin Cancer Res. 2005. 11:5146–5152.

25. Qin SL, Chen XJ, Xu X, Shou JZ, Bi XG, Ji L, et al. Detection of chromosomal alterations in bladder transitional cell carcinomas from Northern China by comparative genomic hybridization. Cancer Lett. 2006. 238:230–239.

26. Kim EJ, Kim WJ. The causal relationship between RUNX3 and bladder tumor. Korean J Urol. 2005. 46:1192–1198.

27. Kim EJ, Kim YJ, Jeong P, Ha YS, Bae SC, Kim WJ. Methylation of the RUNX3 promoter as a potential prognostic marker for bladder tumor. J Urol. 2008. 180:1141–1145.

28. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006. 49:466–475.

29. Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, Palou J, Vicente-Rodriguez J. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol. 2000. 163:73–78.